NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company
NetraMark Holdings (AIAI.TO)on Monday said it will perform a detailed analysis of a completed mid-to-late stage clinical trial for a biopharmaceutical company developing a central nervous system therapy.The AI company, operating in the clinical-trial space, will perform the analysis of patient-level data using its NetraAI platform. The results will help the client develop insights to optimize dose selection, and enhance patient categorization, NetraMark added."This agreement marks another important commercial win and reflects the growing momentum behind NetraAI," chief executive George Achilleos said. "Our clients are increasingly recognizing that completed clinical trials often contain substantially more information than is captured through conventional analyses."This is NetraMark's ninth commercial contract since the start of its current fiscal year.The company's shares were last seen up C$0.02, or 3.2%, to C$0.64 on the Toronto Stock Exchange.Price: $0.64, Change: $+0.02, Percent Change: +3.23%
